tiprankstipranks
Trending News
More News >
Kuros Biosciences (CH:KURN)
:KURN
Advertisement

Kuros Biosciences (KURN) Price & Analysis

Compare
2 Followers

KURN Stock Chart & Stats


KURN FAQ

What was Kuros Biosciences ’s price range in the past 12 months?
Kuros Biosciences lowest stock price was CHF11.44 and its highest was CHF32.00 in the past 12 months.
    What is Kuros Biosciences ’s market cap?
    Kuros Biosciences ’s market cap is CHF1.01B.
      When is Kuros Biosciences ’s upcoming earnings report date?
      Kuros Biosciences ’s upcoming earnings report date is Aug 14, 2025 which is in 5 days.
        How were Kuros Biosciences ’s earnings last quarter?
        Kuros Biosciences released its earnings results on Mar 11, 2025. The company reported -CHF0.11 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.11.
          Is Kuros Biosciences overvalued?
          According to Wall Street analysts Kuros Biosciences ’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Kuros Biosciences pay dividends?
            Kuros Biosciences does not currently pay dividends.
            What is Kuros Biosciences ’s EPS estimate?
            Kuros Biosciences ’s EPS estimate for its next earnings report is not yet available.
            How many shares outstanding does Kuros Biosciences have?
            Kuros Biosciences has 38,589,950 shares outstanding.
              What happened to Kuros Biosciences ’s price movement after its last earnings report?
              Kuros Biosciences reported an EPS of -CHF0.11 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 2.963%.
                Which hedge fund is a major shareholder of Kuros Biosciences ?
                Currently, no hedge funds are holding shares in CH:KURN

                Company Description

                Kuros Biosciences

                Kuros Biosciences (KURN) is a biopharmaceutical company focused on the development and commercialization of innovative products for tissue repair and regeneration. The company operates primarily within the healthcare sector, specifically targeting the fields of orthobiologics and drug delivery. Kuros Biosciences aims to address unmet medical needs through its proprietary technologies and has developed a range of products designed to enhance bone healing and spinal fusion procedures.

                Kuros Biosciences (KURN) Earnings & Revenues

                KURN Company Deck

                KURN Earnings Call

                Q4 2025
                0:00 / 0:00

                KURN Stock 12 Month Forecast

                Average Price Target

                CHF32.50
                ▲(19.67% Upside)
                {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"CHF11","22":"CHF22","33":"CHF33","16.5":"CHF16.5","27.5":"CHF27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.5025337832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5025337832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.5025337832,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF32.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,16.5,22,27.5,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,26.38942567563077,26.898851351261538,27.408277026892307,27.917702702523076,28.427128378153846,28.936554053784615,29.445979729415384,29.955405405046154,30.464831080676923,30.974256756307692,31.483682431938462,31.99310810756923,{"y":32.5025337832,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,26.38942567563077,26.898851351261538,27.408277026892307,27.917702702523076,28.427128378153846,28.936554053784615,29.445979729415384,29.955405405046154,30.464831080676923,30.974256756307692,31.483682431938462,31.99310810756923,{"y":32.5025337832,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.88,26.38942567563077,26.898851351261538,27.408277026892307,27.917702702523076,28.427128378153846,28.936554053784615,29.445979729415384,29.955405405046154,30.464831080676923,30.974256756307692,31.483682431938462,31.99310810756923,{"y":32.5025337832,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.22,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":13.26,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":16.9,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":17.86,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":27,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":20.85,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":21.35,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.95,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":22.1,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":19.38,"date":1743465600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":26.72,"date":1746057600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.88,"date":1748736000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":25.88,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                Similar Stocks
                Company
                Price & Change
                Follow
                Molecular Partners AG
                Basilea Pharmaceutica
                Idorsia Ltd
                Newron Pharmaceuticals SpA
                Santhera Pharmaceuticals Holding

                Ownership Overview

                0.07%98.09%
                Insiders
                0.07%
                Mutual Funds
                ― Other Institutional Investors
                98.09% Public Companies and
                Individual Investors

                Options Prices

                Currently, No data available
                ---
                Popular Stocks
                What am I Missing?
                Make informed decisions based on Top Analysts' activity
                Know what industry insiders are buying
                Get actionable alerts from top Wall Street Analysts
                Find out before anyone else which stock is going to shoot up
                Get powerful stock screeners & detailed portfolio analysis